for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Accuray Incorporated

ARAY.OQ

Latest Trade

3.45USD

Change

-0.07(-1.99%)

Volume

114,234

Today's Range

3.42

 - 

3.50

52 Week Range

2.36

 - 

5.39

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
3.52
Open
3.50
Volume
114,234
3M AVG Volume
13.58
Today's High
3.50
Today's Low
3.42
52 Week High
5.39
52 Week Low
2.36
Shares Out (MIL)
90.47
Market Cap (MIL)
318.44
Forward P/E
--
Dividend (Yield %)
--

Next Event

Q3 2020 Accuray Inc Earnings Release

Latest Developments

More

Accuray Reports Q2 Earnings Per Share $0.12

Accuray Inc - Sees FY 2021-2023 Revenue Cagr Of 8%-12%

Accuray Posts Q1 Loss Per Share Of $0.11

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Accuray Incorporated

Accuray Incorporated is a radiation oncology company. The Company develops, manufactures and markets medical devices used in radiation therapy for the treatment of cancer patients. Its products include the CyberKnife Systems, the TomoTherapy Systems, and the Radixact Delivery Treatment Platform. Its technologies, the CyberKnife and TomoTherapy Systems, are designed to deliver treatments, including stereotactic radiosurgery (SRS), stereotactic body radiation therapy (SBRT), intensity modulated radiation therapy (IMRT), image guided radiation therapy (IGRT) and adaptive radiation therapy. The CyberKnife Systems are robotic systems that are used to treat various types of cancer and tumors throughout the body. The CyberKnife Systems track, detect and correct for tumor and patient movement in real-time during the procedure. The TomoTherapy Systems include the TomoTherapy H Series with configuration options of TomoH, TomoHD and TomoHDA.

Contact Info

1310 Chesapeake Ter

+1.408.7164600

http://www.accuray.com/

Executive Leadership

Louis J. Lavigne

Independent Chairperson of the Board

Joshua H. Levine

President, Chief Executive Officer, Director

Shigeyuki Hamamatsu

Chief Financial Officer, Senior Vice President

Patrick Spine

Senior Vice President, Chief Administrative Officer

Jesse Chew

Senior Vice President, General Counsel, Secretary

Key Stats

2.00 mean rating - 5 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2017

0.4K

2018

0.4K

2019

0.4K

2020(E)

0.4K
EPS (USD)

2017

-0.330

2018

-0.280

2019

-0.190

2020(E)

-0.008
Price To Earnings (TTM)
--
Price To Sales (TTM)
0.78
Price To Book (MRQ)
5.68
Price To Cash Flow (TTM)
36.26
Total Debt To Equity (MRQ)
328.33
LT Debt To Equity (MRQ)
328.33
Return on Investment (TTM)
-0.47
Return on Equity (TTM)
-0.28

Latest News

Latest News

BRIEF-Accuray Q3 Loss Per Share $0.10

* Q3 EARNINGS PER SHARE VIEW $-0.05 -- THOMSON REUTERS I/B/E/S

BRIEF-Apollo Hospitals In India To Acquire Two Accuray Radixact Systems

* APOLLO HOSPITALS IN INDIA TO ACQUIRE TWO ACCURAY RADIXACT® SYSTEMS

BRIEF-Accuray Retires February 2018 Convertible Notes

* ACCURAY RETIRES FEBRUARY 2018 CONVERTIBLE NOTES Source text for Eikon: Further company coverage:

BUZZ-Accuray: RBC, Jefferies raise PTs after results

** Radiation and oncology device maker's shares up 7.69 pct at $5.6 premarket

BRIEF-Accuray Reports Q2 Loss Per Share $0.06

* ACCURAY FISCAL SECOND QUARTER REVENUE EXCEEDS $100 MILLION AND INCREASES 15 PERCENT YEAR-OVER-YEAR; GROSS ORDERS OF $77.9 MILLION; BACKLOG UP 10 PERCENT

BRIEF-Beverly Huss Joins Accuray Board Of Directors

* ACCURAY INC - WITH APPOINTMENT OF HUSS, CO'S BOARD CONSISTS OF SEVEN MEMBERS Source text for Eikon: Further company coverage:

BRIEF-Accuray Elects Net Share Settlement For 3.50 Pct Series A Convertible Senior Notes

* ACCURAY ELECTS NET SHARE SETTLEMENT FOR 3.50% SERIES A CONVERTIBLE SENIOR NOTES DUE 2018

BRIEF-Accuray Inc reports Q1 loss per share $0.11

* Accuray generated $55.6 million in first quarter gross orders; revenue increased 5 percent year over year

BRIEF-European Court Of Appeal rejects Varian's attempt to reverse customer purchase of Accuray TomoTherapy system

* European Court Of Appeal rejects Varian's attempt to reverse customer purchase of Accuray TomoTherapy system

BRIEF-Accuray reports Q4 loss per share of $0.06

* Accuray reports fourth quarter and fiscal 2017 financial results

BRIEF-Accuray issues $85 mln principal amount of 3.75 pct convertible senior notes

* Accuray Inc says on August 7, issued $85 million aggregate principal amount of its 3.75% convertible senior notes due 2022 - sec filing Source text: (http://bit.ly/2umHI40) Further company coverage:

BRIEF-Accuray says receives 510(k) clearance for IDMS data management system upgrade for Tomotherapy system

* Says receives 510(k) clearance for IDMS data management system upgrade for Tomotherapy system Source text for Eikon: Further company coverage:

BRIEF-Accuray enhances capital structure through convertible debt transactions

* Accuray Inc - company has also entered into agreements to privately sell $32 million aggregate principal amount of new notes for cash to certain other investors

BRIEF-Neuro Spinal Hospital in Dubai to buy Accuray Cyberknife and Radixact Systems

* Accuray Inc - deal was entered into backlog during Accuray's fourth fiscal quarter which ended June 30, 2017

BRIEF-Accuray Inc signs new revolving loan agreement

* Closed a new $52 million senior secured revolving loan facility with Midcap Financial Trust Source text for Eikon: Further company coverage:

BRIEF-Accuray reports prelim data from phase I trial of breast cancer cure treated with Cyberknife System

* Prelim data from phase I trial evaluating adjuvant stereotactic partial breast irradiation in early stage breast cancer patients treated with Cyberknife System

BRIEF-Accuray Q3 loss per share $0.06

* Accuray Inc - gross product orders totaled $83.8 million for 2017 fiscal Q3 compared to $56.4 million for prior fiscal year period

BRIEF-Brian Grossman reports 5 pct passive stake in Accuray Inc as of March 6 - SEC filing

* Brian Grossman reports 5.0 percent passive stake in Accuray Inc as of March 6 - SEC filing Source text: (http://bit.ly/2neXxWb) Further company coverage:

BRIEF-Accuray on March 10, co entered into an amendment to financing agreement dated as of Jan. 11, 2016

* On March 10, co entered into an amendment to financing agreement dated as of January 11, 2016 - sec filing

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up